Clicky

Rocket Pharmaceuticals, Inc.(RCKT)

Description: Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has clinical-stage lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; and leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction It also has additional pre-clinical stage LVV programs include pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia; and infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption. In addition, the company has an adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO Inc. The company also has a research and collaboration agreement with Lund University; and strategic collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc. is headquartered in New York, New York.


Keywords: Medicine Biotechnology Immune System Bone Heart Failure Anemia Bone Marrow Genetic Disorder Red Blood Cell Cancer Research Blood Cells Fanconi Anemia Petros Stanford University School Of Medicine Lund University Pyruvate Kinase Deficiency

Home Page: rocketpharma.com

RCKT Technical Analysis

9 Cedarbrook Drive
Cranbury, NJ 08512
United States
Phone: 609 659 8001


Officers

Name Title
Dr. Gaurav D. Shah M.D. CEO & Director
Ms. Kinnari Patel M.B.A., MBA, Pharm.D., PharmD Pres & COO
Mr. Martin Louis Wilson J.D. Gen. Counsel, Chief Compliance Officer & Sr. VP
Mr. Jonathan Schwartz Chief Medical Officer & Sr. VP of Clinical Devel.
Mr. John C. Militello CPA, CPA Interim Principal Financial Officer, VP, Sr. Controller, Treasurer & Principal Accounting Officer
Mr. Mayo Pujols Chief Technical Officer, Exec. VP & Director
Mayur Kasetty M.B.A., M.D. Bus. Devel. & Operations and Investor Relations Lead
Ms. Jessie Yeung M.B.A. VP of Investor Relations & Corp. Fin.
Kevin Giordano Director of Corp. Communications
Ms. Isabel Carmona J.D. Sr. VP & Chief HR Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

GIC Sector: Health Care
GIC Group: Pharmaceuticals, Biotechnology & Life Sciences
GIC Industry: Biotechnology
GIC Sub-Industry:
Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 4.0724
Price-to-Sales TTM: 0
IPO Date: 2015-02-18
Fiscal Year End: December
Full Time Employees: 151
Back to stocks